Lantheus Holdings(US:LNTH)2021-11-04 20:33Q3 2021 Financial Performance - The company reported worldwide revenues of $102.1 million, a 15.3% increase year-over-year[39, 41] - Adjusted EPS increased by 127.4% from $0.04 in Q3 2020 to $0.08 in Q3 2021[39] - Free cash flow decreased by 60.3% from $4.8 million in Q3 2020 to $1.9 million in Q3 2021[39] Product Performance - DEFINITY sales increased by 14.5%, with revenues of $57.6 million[41, 66] - TechneLite sales increased by 7.4%, with revenues of $22.7 million[41, 66] - Radiopharmaceutical oncology revenues increased by 167.5%, with revenues of $8.9 million[41, 66] PYLARIFY Launch and Expansion - PYLARIFY's manufacturing and distribution network expanded significantly, covering approximately 70% of the U S population by the end of Q3, up from approximately 6% at the start of the quarter[15] - The company contracted with approximately two-thirds (65%) of its targeted academic institutions in the U S for PYLARIFY[24, 25] Financial Guidance - The company updated its full-year 2021 revenue guidance to $405 million - $410 million[50, 51] - The company updated its full-year 2021 adjusted fully diluted EPS guidance to $0.40 - $0.43[50, 51]